Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis.
Level 4 - case-series / case-control
Comparative case series / tissue analysis of human specimens (3 treated vs. 2 untreated)
PubMed 38781434 · doi:10.1093/ejendo/lvae055
What was done
Single-cell RNA sequencing (scRNA-seq) was performed on five surgically resected prolactinomas (3 from cabergoline-treated patients and 2 from treatment-naive patients) to evaluate cellular composition and transcriptional differences across tumor, stromal, and immune compartments.
What was found
Six major cell populations were identified across the samples: tumor (88.2%), immune (5.6%), stromal (4.9%), progenitor cells (0.6%), proliferating cells (0.4%), and erythrocytes (0.2%). Tissues from cabergoline-treated patients showed reduced expression of hormone secretion regulatory genes (SCG2, VGF, TIMP1, NNAT, and CALD1), a higher stromal cell population, and increased infiltration of activated CD8+ T cells expressing cytotoxic markers (perforin, GZMB, GNLY, KLRD1), CCL5, and CD25 (IL2R). Specific quantitative comparisons, fold-changes, and p-values were not reported in the abstract.
Why it matters
The study suggests that cabergoline acts beyond direct pituitary tumor hormone suppression by remodeling the tumor microenvironment and promoting cytotoxic CD8+ T cell activation.
Limits
The sample size is very small (n = 5 total; 3 treated and 2 untreated). All tumors required surgical resection, which introduces selection bias toward medically refractory or complicated cases. The abstract does not report exact quantitative effect sizes or functional validation assays.
Cited by
- supports Prescription drugs such as cabergoline inhibit prolactin secretion.